Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study

Documenti analoghi

• Clinicopathological Characteristics of Upper Tract Urothelial Cancer With Loss of Immunohistochemical Expression of Mismatch Repair Proteins
  di: Go Kobayashi, et al.
  Pubblicazione: (2025)
• Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations—A Case Series
  di: Roosvelt Tessa Djambong, et al.
  Pubblicazione: (2026)
• Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real‐World Multicenter Retrospective Study
  di: Ryuma Tanaka, et al.
  Pubblicazione: (2026)
• TUBB3 Is Associated With a Poor Prognosis and Basal Subtypes in Upper and Lower Tract Urothelial Carcinoma
  di: Naofumi Nomura, et al.
  Pubblicazione: (2025)
• Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study
  di: Koji Iinuma, et al.
  Pubblicazione: (2026)